Tinzaparin sodium - Generic Drug Details

What are the generic sources for tinzaparin sodium and what is the scope of freedom to operate?

Tinzaparin sodium is the generic ingredient in one branded drug marketed by Leo Pharma As and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for tinzaparin sodium

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	57
Clinical Trials:	13
DailyMed Link:	tinzaparin sodium at DailyMed

Recent Clinical Trials for tinzaparin sodium

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Imperial College London	Phase 4
Michalis Karamouzis	Phase 3
Ministry of Health, France	Phase 3

See all tinzaparin sodium clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for tinzaparin sodium

B01AB	Heparin group
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

US Patents and Regulatory Information for tinzaparin sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leo Pharma As	INNOHEP	tinzaparin sodium	INJECTABLE;INJECTION	020484-001	Jul 14, 2000		DISCN	No	No

Tinzaparin Sodium Market Dynamics, Patent Status, Competition, and Financial Trajectory

Last updated: September 6, 2026

Tinzaparin sodium is a low-molecular-weight heparin (LMWH) marketed primarily under the brand name Innohep by LEO Pharma. Its commercial profile is mature rather than growth-oriented: patent-driven exclusivity has largely expired, U.S. availability has ended, and demand is concentrated in European and selected international hospital markets. Revenue is shaped by anticoagulation volume, procurement pricing, supply reliability, clinical preference, and competition from enoxaparin, dalteparin, unfractionated heparin, and oral anticoagulants.

Product-level revenue is not publicly disclosed by LEO Pharma. The available financial evidence supports a market assessment based on product availability, therapeutic substitution, reimbursement, and company-level reporting rather than a precise global sales forecast.

What is tinzaparin sodium and how is it used?

Tinzaparin sodium is an LMWH derived from unfractionated heparin. It enhances antithrombin activity, with greater inhibition of factor Xa than thrombin. Its principal clinical uses include:

• Treatment of deep-vein thrombosis and pulmonary embolism.
• Prevention of venous thromboembolism in surgical and medical patients.
• Anticoagulation in selected cancer-associated thrombosis settings.
• Anticoagulation during certain dialysis procedures, depending on local labeling.

Innohep is administered subcutaneously. Dosing depends on the indication, body weight, renal function, and local product labeling. Like other heparin products, tinzaparin carries bleeding risk and requires clinical management in patients with renal impairment, thrombocytopenia, or recent surgery.

The European product is regulated through national and European medicines frameworks. Product information differs by country, particularly for oncology, pregnancy, renal impairment, and prophylaxis indications.[1]

What is the FDA and Orange Book status of tinzaparin sodium?

Tinzaparin previously had U.S. approval under the Innohep brand. The product was withdrawn from the U.S. market in 2011 for commercial reasons, not because FDA identified a safety or efficacy problem.[2]

The practical U.S. status is:

Regulatory issue	Status
Historical U.S. brand	Innohep
Active U.S. commercial availability	Not generally available
U.S. withdrawal basis	Commercial reasons
Current U.S. market role	Minimal to none
Orange Book relevance	Historical product listing; no active branded commercial franchise
Main U.S. substitutes	Enoxaparin, dalteparin, unfractionated heparin, direct oral anticoagulants

Because tinzaparin is no longer a significant U.S. commercial product, U.S. generic-entry risk is less important than international substitution risk. The main U.S. commercial consequence of withdrawal was the loss of a competing LMWH rather than a continuing litigation or patent threat.

When did tinzaparin lose exclusivity?

Tinzaparin’s core composition and early product patents are old and are not the primary commercial barrier today. The active ingredient was introduced in Europe in the 1990s, and its main patent-driven exclusivity period expired years ago.

Exclusivity category	Commercial assessment
Core active-ingredient protection	Expired or commercially exhausted
Original formulation protection	Expired or weak
U.S. market exclusivity	No current commercial significance
Method-of-use protection	Potentially relevant only for narrow, jurisdiction-specific claims
Manufacturing know-how	More important than ordinary composition patents
Regulatory exclusivity	Expired for the original product

No current blockbuster-style patent estate is associated with tinzaparin. Any remaining rights are more likely to concern manufacturing processes, specifications, device presentation, packaging, or narrow clinical uses than the basic anticoagulant molecule.

What patents protect tinzaparin sodium?

The commercial protection for tinzaparin is primarily technical and regulatory rather than patent-exclusive.

Composition and molecular-structure protection

Tinzaparin is a heterogeneous polysaccharide mixture rather than a single small molecule with a simple, fully defined chemical structure. This makes the regulatory and manufacturing analysis different from that for a conventional tablet drug.

The original patent position generally covered:

• Low-molecular-weight heparin compositions.
• Controlled depolymerization of heparin.
• Molecular-weight distribution and anticoagulant activity.
• Preparation of injectable formulations.
• Use in prevention or treatment of thromboembolic disease.

Those categories do not create a meaningful modern monopoly by themselves. Competitors can develop alternative LMWH products if they demonstrate adequate quality, pharmacologic comparability, manufacturing control, and clinical performance under the applicable regulatory pathway.

Manufacturing and process protection

Manufacturing know-how remains a more relevant barrier. Key technical variables include:

• Source and quality of unfractionated heparin.
• Depolymerization chemistry.
• Molecular-weight distribution.
• Anti-Xa and anti-IIa activity ratios.
• Sulfation pattern and impurity profile.
• Batch-to-batch consistency.
• Viral, microbial, and contaminant controls.
• Analytical methods used to characterize the polysaccharide mixture.

These controls may be protected through a mix of patents, confidential know-how, supplier qualification, and regulatory documentation. Process know-how can slow entry without creating a legally durable monopoly.

Formulation and delivery protection

Tinzaparin is generally delivered as a sterile injectable solution in prefilled syringes or other parenteral presentations. Potential protection areas include:

• Concentration and dose presentation.
• Prefilled syringe design.
• Container-closure systems.
• Stability and storage conditions.
• Manufacturing and sterilization methods.

Such rights are normally narrower than active-ingredient patents. Their commercial impact depends on whether a competing manufacturer can use a different presentation or design around the claims.

How many patents cover tinzaparin sodium?

There is no commercially meaningful current patent count that captures the entire global tinzaparin estate. Patent families vary by jurisdiction, continuation practice, claim scope, and legal status. Older composition and process families may remain visible in patent databases even though their enforceable terms have expired.

A practical classification is:

Patent category	Current competitive importance
Original LMWH composition patents	Low
Early tinzaparin preparation patents	Low to moderate, generally expired
Process patents	Moderate where technically valid
Formulation patents	Low to moderate
Prefilled-device patents	Product-specific
Method-of-use patents	Narrow and indication-dependent
Manufacturing know-how	High relative to patent exclusivity

The absence of a strong active patent estate does not make entry simple. Injectable anticoagulants require validated sterile manufacturing, reliable heparin sourcing, regulatory approval, pharmacologic characterization, and hospital purchasing acceptance.

Which companies compete with tinzaparin sodium?

Tinzaparin competes in two markets: the LMWH market and the broader anticoagulation market.

Direct LMWH competitors

Product	Principal company or originator	Competitive position
Lovenox/Clexane, enoxaparin	Sanofi originator; multiple suppliers	Broadest global LMWH presence
Fragmin, dalteparin	Pfizer	Strong hospital and oncology position
Innohep, tinzaparin	LEO Pharma	Established European and selected international presence
Nadroparin	Aspen and regional suppliers	Available in selected countries
Bemiparin	Laboratorios Farmacéuticos ROVI	Stronger in certain European and Latin American markets

Enoxaparin has the strongest competitive position in many markets because of broad availability, extensive clinical use, hospital familiarity, and multiple generic or biosimilar-like suppliers.

Therapeutic substitutes

The broader market includes:

• Unfractionated heparin.
• Fondaparinux.
• Apixaban.
• Rivaroxaban.
• Edoxaban.
• Dabigatran.
• Warfarin.

Direct oral anticoagulants have displaced injectable therapy in several chronic anticoagulation settings. LMWH remains important where rapid parenteral anticoagulation, pregnancy use, cancer-associated thrombosis, perioperative management, or inpatient protocols favor an injectable product.

What is the market outlook for tinzaparin?

Tinzaparin has a stable but constrained outlook. The product is unlikely to regain broad global growth without new indications, expanded geography, a differentiated delivery system, or a meaningful shift in treatment guidelines.

Growth drivers

Demand can remain resilient in the following areas:

• Hospital treatment of acute venous thromboembolism.
• Surgical thromboprophylaxis.
• Cancer-associated thrombosis.
• Pregnancy-related anticoagulation.
• Markets where LMWH remains preferred over oral agents.
• Supply shortages affecting competing heparins.
• Institutional protocols that standardize on tinzaparin.

Market pressures

The principal pressures are:

• Generic and multisource LMWH competition.
• Price-based hospital tenders.
• Substitution by enoxaparin.
• Substitution by direct oral anticoagulants.
• Lower outpatient use of injectable anticoagulants.
• Manufacturing complexity and raw-material dependence.
• Clinical concerns about dosing in severe renal impairment.
• Limited differentiation among LMWH products.

The product’s market is therefore volume-sensitive but price-competitive. A stable unit base can coexist with declining revenue if tender prices fall or hospitals switch to lower-cost alternatives.

What is the financial trajectory for tinzaparin and LEO Pharma?

LEO Pharma does not generally report a separate, audited global revenue line for Innohep in its public financial reporting. As a result, a precise product-level revenue trajectory cannot be established from public company disclosures.

The directional financial profile is clearer:

Period	Financial trajectory
1990s to early 2000s	Growth from adoption of LMWH over unfractionated heparin in several indications
Mid-2000s to 2010	Mature commercial phase with established hospital use
2011	U.S. commercial withdrawal reduced geographic reach
2010s	Price and volume pressure from LMWH competitors and oral anticoagulants
2020s	Mature, regional hospital product with limited organic growth

Tinzaparin’s economics are likely driven by contribution margin rather than high revenue growth. The product benefits from an established manufacturing base and clinical familiarity, but injectable production, quality testing, cold-chain or controlled storage requirements, and heparin sourcing constrain margin expansion.

LEO Pharma’s broader portfolio has included dermatology products and other specialty medicines. The company’s financial exposure to tinzaparin is therefore smaller than its exposure to its leading specialty brands. Without product-level disclosure, Innohep should not be treated as a separately quantifiable driver of LEO Pharma valuation.

What generic entry risks exist for tinzaparin sodium?

Generic or follow-on entry risk is high in jurisdictions where tinzaparin remains commercially active and alternative LMWHs are approved. The risk is more accurately described as multisource or follow-on biologic-like competition than ordinary small-molecule generic substitution.

Regulatory barriers

A prospective competitor must address:

• Equivalence of molecular-weight distribution.
• Anti-Xa and anti-IIa activity.
• Structural and impurity characterization.
• Sterility and endotoxin control.
• Heparin-source traceability.
• Process consistency.
• Clinical or pharmacodynamic evidence required by the regulator.
• Product-specific labeling.

LMWHs are complex mixtures. A competitor may not be automatically interchangeable with the reference product even when its clinical use is similar. Interchangeability rules depend on the jurisdiction and product-specific regulatory assessment.

Commercial barriers

Hospital buyers may prioritize:

• Lowest tender price.
• Supply continuity.
• Established pharmacovigilance.
• National reimbursement status.
• Familiarity among physicians and pharmacists.
• Availability of multiple syringe strengths.
• Reliable supply of pharmaceutical-grade heparin.

These factors can protect an incumbent after patent expiry, but they do not prevent rapid share loss in tender-driven markets.

Are biosimilars a risk to tinzaparin sodium?

Tinzaparin is not a biologic in the same regulatory category as a monoclonal antibody, so conventional biosimilar terminology is not always appropriate. It is a complex heparin-derived medicinal product.

The competitive risk is nevertheless similar to biosimilar risk in three respects:

1. Structural complexity makes analytical comparability central.
2. Manufacturing process differences can affect product attributes.
3. Substitution and interchangeability may depend on regulator and market rules.

The most relevant threat is the entry of additional LMWH products, not biosimilar competition in the narrow legal sense.

What patent litigation and Paragraph IV challenges affect tinzaparin?

No major current U.S. Paragraph IV campaign or active high-value patent litigation is central to tinzaparin’s commercial position. The U.S. withdrawal removed the principal market in which a generic challenger would have had a significant branded opportunity.

Potential disputes in other countries would more likely involve:

• Regulatory approval of a follow-on LMWH.
• Product quality or equivalence.
• Process patents.
• Formulation or device claims.
• Procurement and tender decisions.
• Trademark or trade-dress rights.

The lack of active headline litigation is consistent with an old, mature product whose main competitive questions are regulatory and commercial.

What licensing deals affect tinzaparin sodium?

No major recent global licensing transaction has publicly repositioned tinzaparin as a growth asset. Commercial arrangements are more likely to involve:

• Local distribution.
• Supply agreements.
• Regional marketing rights.
• Hospital procurement contracts.
• Manufacturing or packaging arrangements.

The product’s licensing value is constrained by its mature patent position, limited U.S. opportunity, and competition from established LMWHs. A regional deal may still be attractive where the product has reimbursement, brand recognition, or supply advantages.

How does tinzaparin compare with enoxaparin and dalteparin?

Factor	Tinzaparin	Enoxaparin	Dalteparin
Global commercial scale	Smaller	Largest among LMWHs in many markets	Large
Originator	LEO Pharma	Sanofi	Pfizer
U.S. presence	Withdrawn	Strong	Strong
Patent leverage today	Limited	Limited for core product	Limited for core product
Hospital familiarity	Strong in selected European markets	Broadest	Strong, especially oncology
Oral anticoagulant exposure	High	High	High
Tender vulnerability	High	High	High
Manufacturing barrier	Meaningful	Meaningful	Meaningful
Growth profile	Mature	Mature, with larger base	Mature

Enoxaparin has the strongest scale advantage. Dalteparin benefits from established oncology use. Tinzaparin’s defensible position depends on regional prescribing habits, supply performance, and procurement economics rather than exclusivity.

What are the likely generic launch scenarios?

Three scenarios are commercially credible.

Base case: regional erosion

Tinzaparin remains available in selected markets, with gradual share loss to enoxaparin, other LMWHs, and oral anticoagulants. Pricing declines as tenders become more competitive.

Downside case: accelerated substitution

A lower-priced follow-on tinzaparin or aggressive enoxaparin tender displaces the product in key hospital systems. Volume contracts faster than price reductions can be offset.

Upside case: supply-driven retention

Competitor shortages, expanded use in cancer-associated thrombosis, or stable procurement contracts preserve volume. Revenue remains broadly flat rather than entering a high-growth cycle.

How strong is the tinzaparin patent estate?

The patent estate is weak as a source of current exclusivity and moderate as a manufacturing barrier. Its principal strengths are:

• Established regulatory history.
• Product familiarity.
• Manufacturing know-how.
• Hospital procurement relationships.
• Regional brand recognition.

Its weaknesses are:

• No meaningful U.S. franchise.
• Expired core exclusivity.
• Limited product differentiation.
• Competition from multiple LMWHs.
• Substitution by direct oral anticoagulants.
• Lack of publicly disclosed product-level growth.

Key Takeaways

• Tinzaparin sodium is a mature LMWH marketed mainly as Innohep by LEO Pharma.
• Its U.S. commercial presence ended in 2011 after withdrawal for commercial reasons.
• Core patent exclusivity is expired or commercially exhausted.
• Current barriers are manufacturing complexity, regulatory comparability, sterile production, and supply reliability.
• Enoxaparin is the principal direct competitor; dalteparin is another major comparator.
• Direct oral anticoagulants limit long-term growth in chronic anticoagulation.
• No major current Paragraph IV campaign or patent litigation is central to the product.
• LEO Pharma does not publicly disclose a separate global Innohep revenue line.
• The most probable financial trajectory is mature, regional, and price-sensitive.
• Generic-entry risk is high in active markets, but regulatory and manufacturing requirements make entry more complex than for a conventional small-molecule generic.

FAQs

Is tinzaparin sodium still sold in Europe?

Yes. Innohep remains marketed in selected European and international markets, although availability and approved indications vary by country.

Is tinzaparin interchangeable with enoxaparin?

Not automatically. Tinzaparin and enoxaparin are different LMWH products with distinct molecular-weight distributions, dosing, labeling, and regulatory treatment. Substitution should follow local clinical and regulatory rules.

Why was Innohep discontinued in the United States?

The U.S. product was withdrawn for commercial reasons. The withdrawal was not identified by FDA as a safety- or efficacy-based market removal.[2]

Is tinzaparin a biosimilar?

No. Tinzaparin is a heparin-derived complex mixture, and its follow-on products are not necessarily regulated under the conventional monoclonal-antibody biosimilar framework.

Does tinzaparin have meaningful patent protection in 2025?

The core product does not have meaningful modern composition-patent protection. Any residual value is more likely to arise from manufacturing know-how, process controls, formulation details, device presentation, or narrow jurisdiction-specific rights.

References

1. LEO Pharma A/S. (n.d.). Innohep 20,000 IU/ml solution for injection: Summary of product characteristics. European medicines product information.

2. U.S. Food and Drug Administration. (2012). Tinzaparin sodium injection, 20,000 IU/mL: FDA drug safety and product status information. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

4. LEO Pharma A/S. (2023). Annual report 2023. LEO Pharma.

5. European Medicines Agency. (n.d.). Guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight heparins. European Medicines Agency.